Francesco Raimondi

Francesco Raimondi

Auto-generated profile, based on publicly available information

Francesco Raimondi

Laboratorio di Biologia Bio@SNS, Scuola Normale Superiore, Piazza dei Cavalieri 7, 56126, Pisa, Italy

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Cell
Verified
Journal Article
Closed access
AIAsuka Inoue
Asuka Inoue
FRFrancesco Raimondi
Francesco Raimondi
FKFrancois Marie Ngako Kadji
Francois Marie Ngako Kadji
GSGurdeep Singh
Gurdeep Singh
TKTakayuki Kishi
Takayuki Kishi
RRRobert Bruce Russell
Robert Bruce Russell

29 November 2010 in Journal of Computational Chemistry
Verified
Journal Article
Open access
PDF file
MSMichele Seeber
Michele Seeber
AFAngelo Felline
Angelo Felline
FRFrancesco Raimondi
Francesco Raimondi
SMStefanie Muff
Stefanie Muff
RFRan Friedman
Ran Friedman
FFFrancesca Fanelli
Francesca Fanelli
Wordom is a versatile, user‐friendly, and efficient program for manipulation and analysis of molecular structures and dynamics. The following new analysis modules have been added since the publication of the original Wordom paper in 2007: assignment of secondary structure, calculation of solvent accessible surfaces, elastic network model, motion cross correlations, protein structure network, shortest intra‐molecular and inter‐molecular communication paths, kinetic grouping analysis, and calculation of mincut‐based free energy profiles. In addition, an interface with the Python scripting language has been built and the overall performance and user accessibility enhanced. The source code of Wordom (in the C programming language) as well as documentation for usage and further development are available as an open source package under the GNU General Purpose License from http://wordom.sf.net. © 2010 Wiley Periodicals, Inc. J Comput Chem, 2011

1 July 2019 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
VWVictoria Wu
Victoria Wu
HYHuwate Yeerna
Huwate Yeerna
Nijiro NohataNijiro Nohata
Nijiro Nohata
JCJoshua Chiou
Joshua Chiou
OHOlivier Harismendy
Olivier Harismendy
JGJ.Silvio Gutkind
J.Silvio Gutkind
G protein–coupled receptors (GPCRs) are the largest gene family of cell membrane–associated molecules mediating signal transmission, and their involvement in key physiological functions is well-established. The ability of GPCRs to regulate a vast array of fundamental biological processes, such as cardiovascular functions, immune responses, hormone and enzyme release from endocrine and exocrine glands, neurotransmission, and sensory perception (e.g. vision, odor, and taste), is largely due to the diversity of these receptors and the layers of their downstream signaling circuits. Dysregulated expression and aberrant functions of GPCRs have been linked to some of the most prevalent human diseases, which renders GPCRs one of the top targets for pharmaceutical drug development. However, the study of the role of GPCRs in tumor biology has only just begun to make headway. Recent studies have shown that GPCRs can contribute to the many facets of tumorigenesis, including proliferation, survival, angiogenesis, invasion, metastasis, therapy resistance, and immune evasion. Indeed, GPCRs are widely dysregulated in cancer and yet are underexploited in oncology. We present here a comprehensive analysis of GPCR gene expression, copy number variation, and mutational signatures in 33 cancer types. We also highlight the emerging role of GPCRs as part of oncocrine networks promoting tumor growth, dissemination, and immune evasion, and we stress the potential benefits of targeting GPCRs and their signaling circuits in the new era of precision medicine and cancer immunotherapies.

29 June 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
GGGiambattista Guaitoli
Giambattista Guaitoli
FRFrancesco Raimondi
Francesco Raimondi
BGBernd K. Gilsbach
Bernd K. Gilsbach
YGYacob Gómez-Llorente
Yacob Gómez-Llorente
EDEgon Deyaert
Egon Deyaert
CGChristian Johannes Gloeckner
Christian Johannes Gloeckner
Significance: Leucine-rich repeat kinase 2 (LRRK2) represents a promising drug target for treatment and prevention of Parkinson’s disease (PD), because mutations in LRRK2 are the most common cause of Mendelian forms of the disease. PD-associated LRRK2 variants show decreased GTPase and increased kinase activity. By integrating multiple experimental inputs provided by chemical cross-linking, small-angle X-ray scattering, and a negative-stain EM map, we present, to our knowledge, the first structural model of the full-length LRRK2 dimer. The model reveals a compact folding of the LRRK2 dimer with multiple domain–domain interactions that might be involved in the regulation of LRRK2 enzymatic properties.

29 March 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
CLCristina López
Cristina López
KKKortine Kleinheinz
Kortine Kleinheinz
SASietse M. Aukema
Sietse M. Aukema
MRMarius Rohde
Marius Rohde
SBStephan H. Bernhart
Stephan H. Bernhart
RSReiner Siebert
Reiner Siebert
Burkitt lymphoma (BL) is the most common B-cell lymphoma in children. Within the International Cancer Genome Consortium (ICGC), we performed whole genome and transcriptome sequencing of 39 sporadic BL. Here, we unravel interaction of structural, mutational, and transcriptional changes, which contribute to MYC oncogene dysregulation together with the pathognomonic IG-MYC translocation. Moreover, by mapping IGH translocation breakpoints, we provide evidence that the precursor of at least a subset of BL is a B-cell poised to express IGHA. We describe the landscape of mutations, structural variants, and mutational processes, and identified a series of driver genes in the pathogenesis of BL, which can be targeted by various mechanisms, including IG-non MYC translocations, germline and somatic mutations, fusion transcripts, and alternative splicing.

28 February 2019 in Blood
Verified
Journal Article
Open access
PDF file
RWRabea Wagener
Rabea Wagener
JSJulian Seufert
Julian Seufert
FRFrancesco Raimondi
Francesco Raimondi
SBSusanne Bens
Susanne Bens
KKKortine Kleinheinz
Kortine Kleinheinz
RSReiner Siebert
Reiner Siebert
The new recently described provisional lymphoma category Burkitt-like lymphoma with 11q aberration comprises cases similar to Burkitt lymphoma (BL) on morphological, immunophenotypic and gene-expression levels but lacking the IG-MYC translocation. They are characterized by a peculiar imbalance pattern on chromosome 11, but the landscape of mutations is not yet described. Thus, we investigated 15 MYC-negative Burkitt-like lymphoma with 11q aberration (mnBLL,11q,) cases by copy-number analysis and whole-exome sequencing. We refined the regions of 11q imbalance and identified the INO80 complex-associated gene NFRKB as a positional candidate in 11q24.3. Next to recurrent gains in 12q13.11-q24.32 and 7q34-qter as well as losses in 13q32.3-q34, we identified 47 genes recurrently affected by protein-changing mutations (each ≥3 of 15 cases). Strikingly, we did not detect recurrent mutations in genes of the ID3-TCF3 axis or the SWI/SNF complex that are frequently altered in BL, or in genes frequently mutated in germinal center–derived B-cell lymphomas like KMT2D or CREBBP. An exception is GNA13, which was mutated in 7 of 15 cases. We conclude that the genomic landscape of mnBLL,11q, differs from that of BL both at the chromosomal and mutational levels. Our findings implicate that mnBLL,11q, is a lymphoma category distinct from BL at the molecular level.